Precision Medicine Program
PRISM: A multicentre prospective study of the feasibility and clinical value of a diagnostic service for identifying therapeutic targets and recommending personalised treatment for children and adolescents with high-risk cancer.
ZERO2: Precision Medicine for Children with High-risk and Non-high-risk Cancer
PREDICT: Assessment of the utility of family-based (trio) whole-genome sequencing for cancer predisposition testing in sequential newly diagnosed paediatric and adolescent cancer patients
HoTRODS: High Through-put Robotic Screen of Diffuse Pontine Glioma Study
ECREST: A Phase 1 Study of Intravenous EGFR-ErbituxEDVSMIT (EEDVSMit) in Children with Recurrent / Refractory Solid or CNS Tumours Expressing Epidermal Growth Factor Receptor (EGFR)
INFORM2: Exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies
NORTH: A Phase II Study of Panobinostat in Paediatric, Adolescent and Young Adult Patients with Solid Tumours Including Osteosarcoma, Malignant Rhabdoid Tumour/Atypical Teratoid Rhabdoid Tumours and Neuroblastoma.
PABLO: TCR α+β+/CD19+ cell depleted haploidentical donor stem cell transplantation for paediatric patients.
DART: Phase I/II trial of deflexifol for refractory/recurrent paediatric ependymoma
LEVI'S CATCH: LEVeragIng Chimeric Antigen Receptor-Expressing T Cells for CHildren with Diffuse Midline Glioma
SIOPEN LINES: European Low and Intermediate Risk Neuroblastoma Protocol.
LOGGIC: Phase III, randomised, international multicentre trial for children and adolescents with low-grade glioma.
HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe-Neuroblastoma/SIOPEN
ASSET: Acute Lymphoblastic Leukaemia Subtype and Side-Effects from Treatment (ASSET study) – Nationwide analysis of severe treatment-related toxicity in childhood Leukaemia.
SCI: Prospective Study Registry of Peripheral Neuroblastic Tumours Presenting With Spinal Canal Involvement (SCI)
ALL Registry: Patient Responses to Treatments: An Acute Leukaemia Registry; Minimal Residual Disease testing; Molecular Subtyping and Biobanking for Future Research